Selamectin (Revolution)

Selamectin is a topical antiparasitic medication belonging to the macrocyclic lactone class, specifically classified as a semi-synthetic avermectin derivative. Marketed primarily under the brand name Revolution (known as Stronghold in some countries), selamectin has become a preferred treatment option for various ectoparasitic and endoparasitic conditions in small mammals due to its convenient topical application and broad spectrum of activity. The medication works through the same fundamental mechanism as other avermectins, binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, causing paralysis and death of susceptible parasites while demonstrating excellent safety margins in mammalian hosts when used appropriately.

The development of selamectin represented an important advancement in veterinary antiparasitic therapy by combining the efficacy of systemic avermectin treatment with the convenience of topical spot-on application. Unlike injectable ivermectin formulations that require veterinary administration or careful owner training, selamectin is applied directly to the skin where it absorbs and distributes systemically throughout the body. This transdermal absorption provides systemic activity against both external parasites such as fleas and mites, as well as certain internal parasites including intestinal roundworms and heartworm larvae. The ease of application has made selamectin particularly popular for use in ferrets and other small mammals where repeated handling for injections may cause significant stress.

Selamectin is commercially available as a ready-to-use topical solution in applicator tubes designed for single-dose administration. The medication comes in various concentration sizes intended for different body weight ranges, originally developed for dogs and cats but used extra-label in small mammals at veterinarian-determined doses. The clear to slightly yellow solution is applied directly to the skin, typically at the base of the skull or between the shoulder blades where the animal cannot easily groom it off. For very small patients such as hamsters or mice, the volume of even the smallest commercial tubes may exceed the appropriate dose, requiring veterinary guidance on partial tube application or the use of veterinary-compounded preparations.

The overall safety and efficacy profile of selamectin in small mammals has been established through years of clinical use, though formal approval is limited to dogs and cats in most regions. Exotic animal veterinarians have developed species-specific protocols based on clinical experience and extrapolation from approved species, making selamectin a commonly recommended treatment for ear mites, fur mites, and flea infestations in ferrets, rabbits, guinea pigs, hedgehogs, and various other small mammal species. The medication's broad spectrum, combined with its practical application method, positions selamectin as a versatile choice for multi-parasite prevention and treatment programs in small mammal patients.

The primary indication for selamectin in small mammals is the treatment and prevention of ear mite infestations, most commonly caused by Otodectes cynotis in ferrets and Psoroptes cuniculi in rabbits. Ear mites cause significant discomfort, characterized by dark waxy debris accumulation in the ear canals, intense head shaking, ear scratching, and potential secondary bacterial or yeast infections. Selamectin's systemic distribution following topical application reaches therapeutic concentrations in ear tissues and sebaceous secretions, effectively eliminating mites throughout the ear canal and surrounding areas. Monthly application can prevent reinfestation in environments where ear mite exposure continues, making it particularly valuable for multi-pet households or rescue situations.

Flea treatment and prevention represents another major use of selamectin in small mammals, particularly in ferrets who may acquire fleas from dogs, cats, or the outdoor environment. Unlike some other flea products that are dangerous for small mammals, selamectin has an established safety record in ferrets and is commonly recommended by exotic animal veterinarians for flea control in this species. The medication kills adult fleas through contact and ingestion and prevents flea egg development, breaking the flea life cycle with consistent monthly use. Guinea pigs and rabbits can also develop flea infestations, though they are less commonly affected than ferrets, and selamectin may be used under veterinary guidance in these species as well.

Sarcoptic mange and various fur mite infestations respond to selamectin therapy, extending its utility beyond ear mites alone. Guinea pigs affected by Sarcoptes scabiei or Trixacarus caviae experience intense pruritus and skin damage that can become severe without treatment. Selamectin provides an alternative to injectable medications for these conditions, potentially reducing handling stress associated with repeated injections. Fur mites in rabbits, including Cheyletiella parasitovorax and Leporacarus gibbus, can be treated with selamectin, as can various mite species affecting hedgehogs, hamsters, and other small mammals. The convenience of topical application makes selamectin particularly appealing for long-term management of chronic or recurrent mite problems.

Internal parasite treatment constitutes an additional benefit of selamectin therapy. The medication demonstrates activity against intestinal roundworms (ascarids) and certain other nematodes, providing some degree of internal parasite control alongside its ectoparasitic effects. In ferrets, selamectin also prevents heartworm disease when administered monthly, which is important in regions where heartworm transmission occurs. This combination of internal and external parasite coverage with a single monthly application simplifies preventive care protocols and improves owner compliance compared to regimens requiring multiple different medications.

Selecting selamectin over alternative treatments depends on various factors including the specific parasites involved, patient species, owner capability for administration, and concurrent health conditions. The topical route of administration makes selamectin advantageous when owners are uncomfortable with injections or when patients are particularly stressed by handling for injectable treatments. For comprehensive parasite prevention programs requiring ongoing monthly treatment, the convenience of topical application often improves compliance compared to schedules requiring veterinary visits for injections. However, the relatively higher cost of selamectin compared to generic ivermectin preparations may influence treatment selection, particularly for multi-animal households or when extended treatment courses are required.

Selamectin dosing in small mammals requires veterinary determination based on the patient's species, body weight, and the specific condition being treated. Although the medication is available in pre-measured applicator tubes intended for dogs and cats, these formulations rarely align perfectly with small mammal dosing requirements. Exotic animal veterinarians calculate appropriate doses based on the patient's weight and may instruct owners on applying partial tube contents or may utilize compounded preparations when precise dosing is critical for very small patients. Owners should never attempt to determine selamectin doses independently, as incorrect dosing can result in treatment failure or potential toxicity.

Topical application of selamectin follows a specific technique to ensure optimal absorption and distribution. The medication is applied directly to the skin, not the fur, at a location where the animal cannot easily groom it off—typically at the base of the skull in ferrets and rabbits, or between the shoulder blades in species where this location is practical. For small rodents, application sites may need to be adjusted based on anatomy and the animal's grooming behavior. The applicator tube tip is used to part the fur and deposit the solution directly onto the skin surface. The application site may appear wet or oily for a short period, but the solution absorbs over several hours.

The frequency of selamectin administration depends on the treatment goals and parasite life cycles. For prevention programs addressing fleas and heartworm in ferrets, monthly application maintains protective levels in the body. Treatment of active mite infestations may require two to three monthly applications to ensure elimination of all parasite life stages, as eggs present at the time of first treatment may hatch and need to be eliminated by subsequent doses. Veterinarians determine the appropriate treatment interval based on the specific clinical situation, and owners should adhere to the prescribed schedule for optimal results.

Species-specific dosing considerations significantly affect selamectin protocols in different small mammals. Ferrets have the most established treatment protocols and typically receive selamectin safely at doses extrapolated from cat dosing on a per-kilogram basis. Rabbits require careful veterinary assessment, and protocols vary based on size and clinical judgment. Guinea pigs, chinchillas, and other rodents may receive selamectin under veterinary guidance, though less clinical data exists for these species. Very small mammals such as hamsters and mice present particular challenges due to their tiny size, and veterinary compounding may be necessary to achieve measurable and appropriate doses.

Compounding of selamectin may be required when treating very small patients or when partial doses from commercial tubes cannot be accurately measured. Veterinary compounding pharmacies can prepare selamectin in alternative concentrations or vehicles to allow precise dosing for small patients. These compounded preparations should be used according to veterinary instructions and within the assigned beyond-use dating. Storage requirements for compounded products may differ from commercial formulations, and pharmacy-provided instructions should be followed carefully.

Owner administration of selamectin requires understanding proper technique to ensure treatment success. After veterinary prescription and instruction, owners typically apply the medication at home on the schedule determined by their veterinarian. The treatment area should not be bathed or wet for at least 24 hours following application to allow complete absorption. The animal should be monitored after application for any signs of skin irritation or adverse reaction at the application site. If the animal grooms the application site immediately after treatment, contact the veterinarian for guidance on whether the dose should be repeated or if the amount absorbed will be sufficient for therapeutic effect.

Selamectin is generally well-tolerated in small mammals when used at appropriate doses, with side effects being relatively uncommon and typically mild. The most frequently reported adverse effect is temporary hair loss or skin irritation at the application site. Some animals may experience transient fur loss where the medication was applied, which usually resolves over one to two weeks as the fur regrows. Mild skin irritation, including redness or flaking at the application site, may occur in sensitive individuals but typically does not require treatment and resolves spontaneously.

Gastrointestinal effects from selamectin are less common than with orally administered antiparasitics and generally mild when they occur. Some patients may experience decreased appetite or soft stools following application, though these effects are usually transient. Importantly, selamectin does not carry the same risk of fatal dysbiosis associated with certain antibiotics in hindgut-fermenting species such as guinea pigs, chinchillas, and hamsters. The antiparasitic mechanism of selamectin does not significantly disrupt beneficial intestinal bacteria, making it safer than many other medications in species with sensitive gastrointestinal flora.

Species-specific adverse reactions to selamectin have been reported occasionally. Ferrets may develop salivation if they groom the application site before the product has fully absorbed, though this represents taste reaction rather than toxicity and resolves without treatment. Some rabbits have shown signs of mild lethargy following selamectin application, which typically resolves within 24-48 hours. Individual animals of any species may demonstrate hypersensitivity reactions, manifested as excessive scratching, skin irritation, or behavioral changes, and these patients should be evaluated by a veterinarian and potentially switched to alternative treatments.

Serious side effects from selamectin at appropriate doses are rare but can occur, particularly in very young animals, debilitated patients, or in cases of significant overdose. Signs of selamectin toxicity parallel those of other avermectin compounds and may include ataxia, tremors, dilated pupils, excessive salivation, disorientation, and in severe cases, seizures or coma. These neurotoxic effects result from drug penetration into the central nervous system beyond safe levels. Because commercial tubes contain volumes intended for larger animals, accidental overdose is possible if incorrect amounts are applied to small mammal patients, underscoring the importance of veterinary dose calculation.

Owners should monitor their pets following selamectin application and contact their veterinarian if concerning signs develop. Mild application site reactions can be observed for worsening but usually require no intervention. Signs of systemic toxicity including incoordination, weakness, tremors, or neurological abnormalities warrant immediate veterinary attention. When administered according to veterinary instructions and at appropriate doses, serious adverse effects are uncommon, and selamectin remains one of the safer antiparasitic options available for small mammal patients.

Selamectin is contraindicated in animals with known hypersensitivity to selamectin or other avermectin compounds. Patients who have experienced allergic reactions, significant skin irritation, or systemic adverse effects following previous selamectin application should not receive the medication again. Alternative antiparasitic treatments should be selected for these individuals, and the sensitivity should be documented in medical records to prevent inadvertent re-exposure. Cross-reactivity between different avermectin compounds may occur, so animals sensitive to ivermectin or moxidectin should receive selamectin with caution if at all.

Species contraindications for selamectin in the small mammal context are less clearly defined than for some other medications, as the drug has demonstrated reasonable safety across multiple species when properly dosed. However, veterinary caution is warranted when using selamectin in species for which limited safety data exists. Very small rodents including mice, dwarf hamsters, and similar tiny species require especially careful dose calculation due to their miniature size, and some practitioners prefer alternative medications for these patients. Any species not commonly treated with selamectin should be evaluated on an individual basis by a veterinarian experienced with that species.

Age considerations affect selamectin use in small mammals. The medication should not be used in very young animals whose systems are immature and potentially more susceptible to adverse effects. Specific age cutoffs for selamectin use vary by species, but generally, neonatal and very young small mammals should not receive the medication until they have reached an appropriate developmental stage as determined by veterinary assessment. Geriatric animals or those with significantly compromised health status may also warrant additional caution, as alterations in drug distribution or metabolism could affect safety.

Pregnancy and lactation status influence selamectin prescribing decisions, though the medication has been used in pregnant and nursing animals when the benefits outweigh potential risks. Selamectin does transfer across the placenta and is excreted in milk, exposing fetuses and nursing young to the drug. In breeding situations or when pregnancy status is known, the decision to use selamectin should involve careful veterinary consideration of the parasitic condition's severity versus potential risks to offspring. Some exotic animal veterinarians prefer to delay treatment until after nursing is complete when the parasitic burden permits this approach, while severe infestations may require treatment regardless of reproductive status.

Selamectin may interact with other medications that affect P-glycoprotein function or compete for similar metabolic pathways. P-glycoprotein serves as an important efflux pump that helps limit drug concentrations in sensitive tissues including the brain. Medications that inhibit P-glycoprotein can potentially increase selamectin concentrations in the central nervous system, raising the risk of neurotoxicity. Known P-glycoprotein inhibitors include certain antifungal medications such as ketoconazole and itraconazole, which may be used in small mammals for dermatophytosis or systemic fungal infections. When concurrent use is necessary, veterinarians may adjust dosing or increase monitoring for adverse effects.

Concurrent use of multiple avermectin-class antiparasitics should be avoided or carefully managed due to cumulative effects. Using selamectin simultaneously with ivermectin, moxidectin, or other macrocyclic lactones could result in additive toxicity risks. When switching between these medications or when a patient has recently received another avermectin compound, appropriate intervals should be observed before initiating selamectin therapy. Veterinarians calculate total exposure and timing to prevent dangerous cumulative effects while ensuring adequate parasite control.

Interactions with dietary components and supplements are generally minimal for topically applied selamectin, distinguishing it from orally administered antiparasitics where food interactions may affect absorption. Since selamectin absorbs through the skin rather than the gastrointestinal tract, dietary factors have less influence on drug levels. However, the overall nutritional status and body condition of the patient can affect drug distribution and metabolism. Malnourished animals or those with altered fat stores may handle the medication differently than healthy individuals, though this represents a patient factor rather than a true drug-diet interaction.

Safe combinations with selamectin include many medications commonly used in small mammal practice. The medication can generally be used alongside antibiotics (species-appropriate ones), anti-inflammatory drugs, pain medications, and supportive care treatments without significant interactions. For small mammals with parasitic conditions complicated by secondary infections or other concurrent problems, combination therapy using selamectin with other appropriate medications represents standard practice. Complete disclosure of all medications and supplements to the prescribing veterinarian ensures comprehensive interaction screening and safe treatment planning.

Application site monitoring represents an important precaution when using selamectin in small mammals. The medication should be applied only to intact, healthy skin, as application to broken or irritated skin may result in increased systemic absorption or local irritation. After application, the site should be observed for excessive redness, swelling, or ongoing irritation that might indicate a sensitivity reaction. Animals that persistently scratch or chew at the application site should be evaluated by a veterinarian, as this behavior may indicate irritation or could result in oral ingestion of the product.

Species-specific warnings for selamectin use require attention in small mammal practice. While ferrets have the most established safety record with selamectin use, other species have less clinical data supporting their treatment. Rabbits generally tolerate selamectin well but require appropriate veterinary dosing rather than direct extrapolation from dog or cat doses. Guinea pigs, chinchillas, and other rodents can receive selamectin under veterinary guidance, but practitioners should remain alert for adverse effects in species with limited treatment history. Novel species or those uncommonly seen in veterinary practice warrant particular caution and careful monitoring.

Monitoring during selamectin treatment should assess both safety and efficacy. Owners should observe for any signs of adverse reaction, particularly in the 24-72 hours following application when drug absorption and distribution peak. Simultaneously, improvement in the parasitic condition should be tracked through resolution of clinical signs. Follow-up veterinary examinations may include repeat skin scrapings or ear examinations to confirm treatment success, especially for mite infestations. If the condition fails to improve or worsens despite treatment, veterinary re-evaluation can determine whether the diagnosis was correct, whether the dose was adequate, or whether alternative treatments are needed.

Human safety during selamectin application requires standard precautions. The product should not be applied in areas of the home where food is prepared, and hands should be washed thoroughly after handling the medication or treated animals. While selamectin at therapeutic doses is not considered highly toxic to humans, avoiding unnecessary exposure is appropriate. Children should not handle selamectin applicators or recently treated animals until the medication has fully absorbed. The application site should not be touched until dry, and owners should avoid allowing treated pets to lick their faces until absorption is complete.

Environmental management supports successful selamectin treatment for parasitic conditions. While the medication eliminates parasites on the animal, environmental reservoirs of fleas or mites can lead to reinfestation. Thorough cleaning of the pet's environment, including bedding, enclosures, and areas where the pet spends time, helps eliminate off-host parasite stages. For flea infestations, environmental treatment with appropriate products may be necessary alongside patient treatment. When treating mites in small mammals, replacing disposable bedding and cleaning enclosures reduces reinfection risk and supports faster resolution of the condition.

Commercial selamectin products should be stored according to manufacturer instructions to maintain stability and efficacy. The medication should be kept at controlled room temperature, typically below 86°F (30°C), and protected from light exposure. Original packaging provides light protection and should be retained until the product is used. Applicator tubes should remain sealed until immediately before use, as the product may degrade following exposure to air. Products stored under inappropriate conditions may have reduced efficacy and should not be used past their expiration dates.

Compounded selamectin preparations may have different storage requirements and shorter stability periods than commercial products. Veterinary compounding pharmacies provide specific storage instructions for their preparations, which should be followed precisely. Some compounded products may require refrigeration while others should be stored at room temperature—pharmacy instructions should be followed rather than assuming requirements match commercial formulations. Beyond-use dates assigned by compounding pharmacies are typically shorter than commercial product expiration dates, reflecting the different stability characteristics of compounded preparations.

Safe handling and disposal of selamectin follows standard pharmaceutical practices. Unused portions of commercial applicator tubes should not be stored for later use due to contamination and stability concerns; instead, they should be disposed of according to local pharmaceutical disposal guidelines. Empty applicators can typically be discarded in regular household trash after ensuring no product remains. Products should never be flushed down drains or disposed of in ways that could contaminate water supplies. Veterinary clinics and some pharmacies offer pharmaceutical take-back programs for proper disposal of unused medications.

Hamsters, gerbils, mice, and rats present unique challenges for selamectin administration due to their very small body sizes. The smallest commercial selamectin applicators contain volumes intended for puppies or kittens, which far exceed the appropriate dose for a hamster weighing 30-40 grams. Veterinary guidance is essential for these species, and compounded preparations may be necessary to achieve accurate dosing. When selamectin is used in small rodents, careful monitoring for adverse effects is important, and some practitioners prefer alternative treatments such as injectable ivermectin where dosing precision may be easier to achieve. Mite infestations in these species, including Myobia and Radfordia in mice and rats, can be treated with selamectin when properly dosed.

Guinea pigs and chinchillas may receive selamectin for treatment of mite infestations, including the sarcoptic mange that can severely affect guinea pigs. The topical application route offers advantages in these species by reducing the handling and restraint required for injectable treatments, potentially decreasing stress in already uncomfortable patients. These hindgut-fermenting species are highly sensitive to dysbiosis from certain antibiotics, but selamectin does not share this risk and can be safely used from a gastrointestinal standpoint. Dosing must be calculated by veterinarians familiar with these species, as protocols developed for dogs and cats do not directly transfer to cavies and chinchillas.

Ferrets represent the small mammal species with the most extensive clinical experience with selamectin use. The medication is commonly prescribed for ear mite treatment and prevention, flea control, and heartworm prevention in ferrets living in endemic areas. Ferrets generally tolerate selamectin well, and their size allows for more straightforward dosing using commercial products compared to tiny rodent species. Monthly selamectin application has become a standard preventive care recommendation for ferrets in many practices, providing protection against multiple parasites with convenient topical administration.

Hedgehogs, sugar gliders, and other exotic small mammals may be treated with selamectin under veterinary guidance for appropriate indications. Hedgehogs are particularly prone to mite infestations and frequently benefit from antiparasitic treatment, with selamectin offering a topical option when owners prefer to avoid injectable medications. Sugar gliders are tiny and require careful dose calculation, with some veterinarians preferring other treatment options for this species. Each unusual species should be evaluated individually by a veterinarian with exotic animal experience to determine whether selamectin is appropriate and, if so, what dose and protocol should be used.

Ivermectin represents the most closely related alternative to selamectin, sharing the macrocyclic lactone mechanism of action but typically administered via injection or oral routes rather than topically. Injectable ivermectin remains widely used in small mammal practice due to its lower cost and long track record of efficacy. The choice between selamectin and ivermectin often depends on practical factors including owner comfort with administration methods, patient stress during handling, and whether the convenience of topical application justifies the typically higher cost of selamectin products. For the same conditions that selamectin treats, ivermectin generally provides equivalent efficacy when properly dosed.

Other topical antiparasitic options for small mammals include imidacloprid (Advantage) for flea control and fipronil (Frontline) in certain species. Imidacloprid is used in ferrets and some other small mammals for flea treatment but does not provide the same broad-spectrum coverage as selamectin against mites and internal parasites. Fipronil has significant safety concerns in some small mammal species and is not recommended for rabbits, making selamectin a preferred option when broad antiparasitic coverage with topical application is desired. These alternatives may be appropriate for specific situations under veterinary guidance but generally do not replace selamectin for comprehensive parasite management.

Combination approaches may utilize selamectin alongside other treatments for complicated parasitic conditions or when multiple parasite types require different medication classes. Environmental flea control products complement selamectin's on-animal treatment for comprehensive flea management in infested households. For mite infestations, some veterinarians combine topical selamectin with environmental cleaning protocols and supportive care for affected skin. When internal and external parasites coexist, selamectin's broad spectrum may reduce the number of medications needed compared to using separate treatments for each parasite type. Treatment plans should be developed by veterinarians based on the individual patient's needs and the specific parasites present.